Headline Which of this year's launches will be future blockbusters?
Source EP Vantage
Company Roche, Eli Lilly, Johnson & Johnson, Wyeth, ZymoGenetics 
Date January 04, 2008
 

Of the new drugs due to be launched this year, four are forecast to be blockbusters by 2012, with Actemra, the monoclonal antibody made by Roche to treat rheumatoid arthritis, leading the pack by a considerable margin.

According to consensus forecasts from EvaluatePharma, analysts see sales of the drug reaching $89m this year, jumping to an impressive $2.25bn in four years' time. Success hinges on regulatory clearance. With a PDUFA date of September 19 set in the US and a decision expected in Europe in the second half of the year, the latter part of 2008 will be a nail-biter for the Swiss pharma giant.
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd